A cost analysis of upfront DPYD genotype–guided dose individualisation in fluoropyrimidine-based anticancer therapy
Linda M. Henricks(The Netherlands Cancer Institute), Carin A.T.C. Lunenburg(Leiden University Medical Center), Femke M. de Man(Erasmus MC), Didier Meulendijks(The Netherlands Cancer Institute), Geert Frederix(University Medical Center Utrecht), Emma Kienhuis(Erasmus MC), Geert-Jan Creemers(Radboud University Nijmegen), Arnold Baars(Ziekenhuis Gelderse Vallei), Vincent O. Dezentjé(The Netherlands Cancer Institute), Alexander L.T. Imholz(Deventer Ziekenhuis), Frank J. Jeurissen(Medisch Centrum Haaglanden), Johanna E.A. Portielje(Leiden University Medical Center), Rob L. H. Jansen(Maastricht University), Paul Hamberg(Sint Franciscus Gasthuis), Albert J. ten Tije(Amphia Ziekenhuis), Helga Droogendijk(Bravis Ziekenhuis), Miriam Koopman(Utrecht University), Peter Nieboer, Marlène H. W. van de Poel(Laurentius Ziekenhuis), Caroline M.P.W. Mandigers(Canisius-Wilhelmina Ziekenhuis), Hilde Rosing(The Netherlands Cancer Institute), Jos H. Beijnen(Utrecht University), Erik van Werkhoven(The Netherlands Cancer Institute), André B. P. Kuilenburg(Amsterdam University Medical Centers), Ron H. N. van Schaik(Erasmus MC), Ron H.J. Mathijssen(Erasmus MC), Jesse J. Swen(Leiden University Medical Center), Hans Gelderblom(Leiden University Medical Center), Annemieke Cats(The Netherlands Cancer Institute), Henk‐Jan Guchelaar(Leiden University Medical Center), Jan H.M. Schellens(Utrecht University)
Cited by 90Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis